Back to Bills
SENATE-BILL 475119th Congress

SENATE-BILL 475: S.475 - Alternatives to PAIN Act

Introduced: February 6, 2025
Status: Referred to Committee
supported

AI-Powered Summary

Generated by AI Analysis

SENATE-BILL 475 aims to enhance access to non-opioid pain management drugs for Medicare Part D beneficiaries by eliminating deductibles and placing qualifying drugs on the lowest cost-sharing tier. This legislation addresses major themes of healthcare access and the opioid crisis by promoting non-opioid alternatives, thereby improving affordability and accessibility for individuals suffering from chronic pain or recovering from surgery. Key provisions include the prohibition of step therapy and prior authorization for qualifying drugs, which enhances patient autonomy in treatment decisions. The definition of qualifying drugs is tied to FDA approval and cost thresholds, ensuring safety and efficacy while potentially limiting the scope of available treatments. Implementation requires insurance plans to comply with these mandates, with a focus on improving public health outcomes. Potential implications include the right to healthcare access and concerns about government overreach in insurance coverage requirements, as well as the balance of power between patient autonomy and insurance management.

Demographic Impact Analysis

AI Demographics Analysis

Summary

Overall Constitutional Implications

The bill is designed to improve access to essential health care services, particularly for individuals suffering from chronic pain. By eliminating cost-sharing and prohibiting step therapy, it aims to ensure that all individuals, regardless of demographic characteristics, can access non-opioid pain management options without undue delay or financial burden.

Key Individual Rights Affected

  • Right to Health Care Access
  • Equal Protection under the Law
  • Due Process Rights

Constitutional Provisions

  • 14th Amendment - Equal Protection Clause
  • Due Process Clause

Potential Constitutional Challenges Or Support

While the bill supports individual rights by facilitating access to non-opioid medications, there may be concerns regarding its implementation across different demographic groups. If disparities in access arise, it could lead to equal protection challenges. Additionally, the balance of power between federal regulations and insurance providers may be contested, raising questions about government overreach.

Summary

SENATE-BILL 475 has the potential to significantly enhance individual rights related to health care access, particularly for vulnerable populations at risk of opioid addiction. By streamlining access to non-opioid alternatives and reducing financial burdens, the bill aligns with constitutional principles of equal protection and due process, although careful monitoring will be necessary to ensure equitable implementation across diverse demographic groups.

Constitutional Analysis

supported

This bill appears to align with constitutional principles. The proposed legislation operates within the established framework of constitutional authority and does not appear to conflict with fundamental rights or the separation of powers.

Analysis generated using AI-powered review of constitutional principles and legal precedents.

Take Action

Text 50409

💡 How to use:

These links will start a conversation with ResistBot. When prompted, mention S. 475 to reference this bill.

Contact Your Representatives

Write to YOUR elected officials about this bill

Rate This Bill

Sign in to save a private rating for this bill and track your civic engagement over time.

Sign In Free

Policy Topics

Timeline

February 6, 2025

Bill Introduced

Current

Referred to Committee

June 12, 2026

Last Updated

Ask the Constitutional AI About This Bill

Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.

Sign In Free to Chat